Svb Leerink Begins Coverage on Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Share on StockTwits

Research analysts at Svb Leerink assumed coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research note issued on Tuesday, Briefing.com Automated Import reports. The brokerage set an “underperform” rating and a $32.00 price target on the biotechnology company’s stock. Svb Leerink’s price objective would indicate a potential downside of 43.28% from the company’s previous close.

A number of other analysts also recently weighed in on the company. Oppenheimer began coverage on Arrowhead Pharmaceuticals in a research note on Thursday, December 12th. They issued a “hold” rating on the stock. Robert W. Baird upgraded Arrowhead Pharmaceuticals from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $39.00 to $70.00 in a research note on Monday, November 25th. BidaskClub downgraded Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 16th. ValuEngine downgraded Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $50.00 price target (up from $24.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, November 19th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $66.00.

Shares of ARWR stock opened at $56.42 on Tuesday. The business’s 50 day moving average is $63.08 and its two-hundred day moving average is $41.94. Arrowhead Pharmaceuticals has a twelve month low of $12.51 and a twelve month high of $73.72. The company has a market capitalization of $5.40 billion, a P/E ratio of 81.77 and a beta of 1.97.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Monday, November 25th. The biotechnology company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.14 by ($0.03). Arrowhead Pharmaceuticals had a net margin of 40.27% and a return on equity of 32.30%. The company had revenue of $43.29 million during the quarter, compared to analysts’ expectations of $36.97 million. Research analysts expect that Arrowhead Pharmaceuticals will post -0.36 EPS for the current year.

In other Arrowhead Pharmaceuticals news, General Counsel Patrick O’brien sold 14,625 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $60.12, for a total transaction of $879,255.00. Following the sale, the general counsel now directly owns 267,406 shares in the company, valued at $16,076,448.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Christopher Richard Anzalone sold 100,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $67.50, for a total value of $6,750,000.00. Following the sale, the chief executive officer now owns 2,048,684 shares in the company, valued at $138,286,170. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 246,089 shares of company stock worth $15,145,844. Company insiders own 4.80% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Municipal Employees Retirement System of Michigan boosted its position in Arrowhead Pharmaceuticals by 1.3% during the third quarter. Municipal Employees Retirement System of Michigan now owns 28,560 shares of the biotechnology company’s stock worth $805,000 after purchasing an additional 380 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in Arrowhead Pharmaceuticals by 96.2% during the third quarter. Nisa Investment Advisors LLC now owns 1,020 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 500 shares in the last quarter. United Services Automobile Association boosted its position in Arrowhead Pharmaceuticals by 2.6% during the second quarter. United Services Automobile Association now owns 20,515 shares of the biotechnology company’s stock worth $544,000 after purchasing an additional 522 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Arrowhead Pharmaceuticals by 10.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,701 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 531 shares in the last quarter. Finally, Comerica Bank boosted its position in Arrowhead Pharmaceuticals by 0.7% during the third quarter. Comerica Bank now owns 89,234 shares of the biotechnology company’s stock worth $3,291,000 after purchasing an additional 627 shares in the last quarter. Institutional investors own 70.33% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

See Also: Resistance Level

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Hasbro, Inc.  Expected to Earn Q1 2020 Earnings of $0.01 Per Share
Hasbro, Inc. Expected to Earn Q1 2020 Earnings of $0.01 Per Share
Halozyme Therapeutics, Inc.  to Post Q1 2020 Earnings of  Per Share, Piper Sandler Forecasts
Halozyme Therapeutics, Inc. to Post Q1 2020 Earnings of Per Share, Piper Sandler Forecasts
Q1 2020 EPS Estimates for Helios Technologies  Boosted by William Blair
Q1 2020 EPS Estimates for Helios Technologies Boosted by William Blair
Aergo Price Down 15.4% This Week
Aergo Price Down 15.4% This Week
Skychain  Market Capitalization Achieves $662,118.00
Skychain Market Capitalization Achieves $662,118.00
EveriToken  Trading Down 27.4% Over Last Week
EveriToken Trading Down 27.4% Over Last Week


 
© 2006-2020 Zolmax.